Entospletinib (GS-9973)
Revision as of 22:36, 13 June 2018 by Warner-admin (talk | contribs) (Text replacement - "Category:Drug index" to "Category:Drugs")
Mechanism of action
Spleen tyrosine kinase (SYK) inhibitor
Preliminary data
CLL
- Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. link to original article PubMed